Get the Stockscreener App
0.8032
0.90%
-0.0073
After Hours:
.80
-0.0032
-0.40%
Atossa Therapeutics Inc stock is traded at $0.8032, with a volume of 754.42K.
It is down -0.90% in the last 24 hours and down -17.20% over the past month.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
See More
Previous Close:
$0.8105
Open:
$0.83
24h Volume:
754.42K
Relative Volume:
1.13
Market Cap:
$114.38M
Revenue:
-
Net Income/Loss:
$-26.91M
P/E Ratio:
-3.6509
EPS:
-0.22
Net Cash Flow:
$-19.57M
1W Performance:
-8.52%
1M Performance:
-17.20%
6M Performance:
-18.87%
1Y Performance:
-28.29%
1-Day Range:
$0.80
$0.8306
1-Week Range:
$0.80
$0.8939
52-Week Range:
$0.5526
$1.66
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Name
Atossa Therapeutics Inc
Sector
Industry
Phone
206.588.0256
Address
10202 5TH AVENUE NE, SEATTLE, WA
Compare ATOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
0.8032 | 114.38M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-18 | Initiated | Maxim Group | Buy |
Atossa Therapeutics Inc Stock (ATOS) Latest News
Millennium Management LLC Purchases Shares of 29,149 Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Purchased by Two Sigma Advisers LP - Defense World
Ascendiant Capital Markets Issues Positive Forecast for Atossa Therapeutics (NASDAQ:ATOS) Stock Price - Defense World
Craig Hallum Upgrades Atossa Therapeutics (NASDAQ:ATOS) to “Strong-Buy” - Defense World
Atossa Therapeutics (ATOS): Ascendiant Capital Raises Price Targ - GuruFocus
Ascendiant Capital raises Atossa Genetics stock price target to $7.50 By Investing.com - Investing.com India
Ascendiant Capital raises Atossa Genetics stock price target to $7.50 - Investing.com
Craig-Hallum Initiates Coverage of Atossa Therapeutics (BMV:ATOS) with Buy Recommendation - Nasdaq
Craig-Hallum Initiates Coverage of Atossa Therapeutics (ATOS) with Buy Recommendation - Nasdaq
This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Craig-Hallum Initiates Coverage on Atossa Therapeutics (ATOS) with Buy Rating | ATOS Stock News - GuruFocus
Atossa Therapeutics at Jefferies Conference: Strategic Moves in Breast Cancer - Investing.com Canada
Craig-Hallum initiates Atossa Genetics stock with buy rating By Investing.com - Investing.com UK
Atossa Therapeutics (ATOS) Receives Buy Rating with Promising Ca - GuruFocus
Atossa Therapeutics (ATOS) Receives Buy Rating with Promising Cancer Drug Potential | ATOS Stock News - GuruFocus
Craig Hallum Initiates Coverage on Atossa Therapeutics With Buy Rating, $4 Price Target - MarketScreener
Atossa Therapeutics (ATOS) Receives Positive Coverage and Price Target | ATOS Stock News - GuruFocus
Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference - Bluefield Daily Telegraph
Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference | ATOS Stock News - GuruFocus
Atossa Therapeutics CEO Reveals Latest Breast Cancer Drug Progress at Major Healthcare Conference - Stock Titan
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by Northern Trust Corp - Defense World
Atossa Therapeutics Reports Q1 2025 Financial Results - TipRanks
Atossa Therapeutics CEO Steven Quay buys $9,886 in common stock - Investing.com Australia
Atossa Therapeutics CEO Steven Quay buys $9,886 in common stock By Investing.com - Investing.com Nigeria
Transcript : Atossa Therapeutics, Inc.Special Call - marketscreener.com
Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 - ACCESS Newswire
Atossa Therapeutics announces issuance of U.S. patent - MSN
Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 | ATOS Stock News - GuruFocus
Atossa CEO to Reveal Latest Phase 2 Results for Next-Gen Breast Cancer Drug in Exclusive Investor Webinar - Stock Titan
HC Wainwright Issues Optimistic Outlook for ATOS Earnings - Defense World
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? - Yahoo Finance
Atossa Therapeutics (ATOS) Reports Promising Phase 2 Trial Resul - GuruFocus
Atossa Therapeutics Announces Full Results from I?SPY?2 Endocrin - GuruFocus
Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen - StreetInsider
Wells Fargo & Company MN Has $68,000 Stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Phase 2 Trial: New Breast Cancer Drug Achieves 77.7% Tumor Shrinkage with Minimal Side Effects - Stock Titan
Atossa Therapeutics Announces First Quarter 2025 Financial Resul - GuruFocus
Atossa Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update - goSkagit
ATOSSA THERAPEUTICS, INC. SEC 10-Q Report - TradingView
Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update | ATOS Stock News - GuruFocus
Barclays PLC Has $181,000 Holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics (ATOS) to Release Quarterly Earnings on Monday - Defense World
Atossa Therapeutics reports progress in breast cancer treatments - MSN
Atossa Therapeutics and Ainos Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - standard-journal.com
JPMorgan Chase & Co. Buys 211,654 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
ATOS: Atossa Therapeutics Secures New Patent for (Z)-endoxifen F - GuruFocus
ATOS: Atossa Therapeutics Secures New Patent for (Z)-endoxifen Formulations | ATOS Stock News - GuruFocus
A look into Atossa Therapeutics Inc (ATOS)’s deeper side - Sete News
LPL Financial LLC Cuts Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics Inc Stock (ATOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atossa Therapeutics Inc Stock (ATOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Remmel H. Lawrence | Director |
Mar 26 '25 |
Buy |
0.70 |
10,000 |
7,000 |
10,257 |
2.13%
1.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):